Shares of Abiomed Inc. plunged by nearly one-third on the Nasdaq stock exchange Thursday after the Danvers company said it is the subject of a federal investigation.
In documents filed with the Securities and Exchange Commission, the cardiac device maker disclosed it has received a subpoena from the US attorney’s office seeking files related to the labeling and marketing of its Impella 2.5 heart pump.
“We are in the process of responding to the subpoena and intend to cooperate fully,” Abiomed said in the filing.
Abiomed’s shares closed Thursday at $13.61, down $6.21, or 31.33 percent, on the Nasdaq.
Robert Weisman can be reached at firstname.lastname@example.org.